Please use this identifier to cite or link to this item:
標題: Recombinant Lipidated HPV E7 Induces a Th-1-Biased Immune Response and Protective Immunity against Cervical Cancer in a Mouse Model
作者: Huang, Chiung-Yi
Jeremy, J.W.Chen
Shen, Kuan-Yin
Chang, Li-Sheng
Yeh, Yi-Chen
Chen, I-Hua
Chong, Pele
Liu, Shih-Jen
Leng, Chih-Hsiang
Project: PLoS ONE, Volume 7, Issue 7
The E7 oncoprotein of human papillomavirus (HPV) is an ideal target for developing immunotherapeutic strategies against
HPV-associated tumors. However, because protein-based immunogens alone are poor elicitors of the cytotoxic Tlymphocyte
(CTL) responses, they have been difficult to exploit for therapeutic purposes. In this study, we report that
a recombinant lipoprotein consisting of inactive E7 (E7m) biologically linked to a bacterial lipid moiety (rlipo-E7m) induces
the maturation of mouse bone marrow-derived dendritic cells through toll-like receptor 2 (TLR2), skews the immune
responses toward the Th1 responses and induces E7-specific CTL responses. We further studied the ability of rlipo-E7m to
provide protection against a TC-1 tumor cell challenge in an animal model. Mice prophylactically immunized with two 10-mg
doses of rlipo-E7m were found to be free of TC-1 tumor growth. Experiments in a therapeutic immunization model showed
that the tumor volume in mice receiving a single dose of rlipo-E7m was less than 0.01 cm3 on day 40, whereas the tumor
volume in mice treated with rE7m was 2.2861.21 cm3. The tumor volume of the entire control group was over 3 cm3. In
addition, we demonstrated that the CD8+ T cells play a major role in anti-tumor immunity when administration of rlipo-
E7m. These results demonstrate that rlipo-E7m could be a promising candidate for treating HPV-associated tumors.
DOI: 10.1371/journal.pone.0040970
Appears in Collections:生物醫學研究所

Show full item record

Google ScholarTM




Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.